Asthma control cost-utility randomized trial evaluation (ACCURATE): The goals of asthma treatment

BMC Pulmonary Medicine

Volumn 11, Issue , 2011, Pages

  Honkoop, Persijn J ^a   Loymans, Rik J B ^b   Termeer, Evelien H ^c   Snoeck Stroband, Jiska B ^a   Bakker, Moira J ^a   Assendelft, Willem J J ^a   Sterk, Peter J ^b   ter Riet, Gerben ^b   Schermer, Tjard R J ^c   Sont, Jacob K ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LEUKOTRIENE RECEPTOR AFFECTING AGENT; NITRIC OXIDE; ANTIASTHMATIC AGENT;

ARTICLE; ASTHMA; CORTICOSTEROID THERAPY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE CONTROL; DISEASE EXACERBATION; DRUG MEGADOSE; EXPIRED AIR; FORCED EXPIRATORY VOLUME; HUMAN; LOW DRUG DOSE; MILD PERSISTENT ASTHMA; MODERATE PERSISTENT ASTHMA; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); ADOLESCENT; ADULT; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST OF ILLNESS; ECONOMICS; FEMALE; FOLLOW UP; MALE; MIDDLE AGED; MULTICENTER STUDY; NETHERLANDS; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTI-ASTHMATIC AGENTS; ASTHMA; COST OF ILLNESS; COST-BENEFIT ANALYSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; QUALITY-ADJUSTED LIFE YEARS; QUESTIONNAIRES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 82055171762     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/1471-2466-11-53     Document Type: Article

References (51)

1. Holgate ST, Price D, Valovirta E. Asthma out of control? A structured review of recent patient surveys. BMC Pulm Med 2006, 6(Suppl 1):s2. 10.1186/1471-2466-6-S1-S2, 1698495, 17140420.
2. Hoogendoorn M, Feenstra TL, Rutten-van Molken MP. Projections of future resource use and the costs of asthma and COPD in the Netherlands. Ned Tijdschr Geneeskd 2006, 150:1243-1250.
3. Vermeire PA, Rabe KF, Soriano JB, Maier WC. Asthma control and differences in management practices across seven European countries. Respir Med 2002, 96:142-9. 10.1053/rmed.2001.1241, 11905548.
4. Rabe KF, Vermeire PA, Soriano JB, Maier WC. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J 2000, 16:802-807. 10.1183/09031936.00.16580200, 11153575.
5. Geijer RMM, Chavannes NH, Muris JWM, Sachs APE, Schermer T, Smeele IJM, Thoonen B, Van der Molen T, Van Schayck CP, Van Weel C, Kolnaar BGM, Grol MH. NHG standaard Astma bij volwassenen. Huisarts Wet 2007, 50:537-551.
6. Global Initiative for Asthma (GINA) Global Strategy for Asthma Management and Prevention. NHLBI/WHO workshop report. 2006, National Institutes of Health, National Heart, Lung and Blood Institute, accessed September 2008, Global Initiative for Asthma (GINA)., http://www.ginasthma.org
7. Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999, 14:902-907. 10.1034/j.1399-3003.1999.14d29.x, 10573240.
8. Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, Pedersen SE. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004, 170:836-844. 10.1164/rccm.200401-033OC, 15256389.
9. O'Byrne PM, Bisgaard H, Godard PP, Pistolesi M, Palmqvist M, Zhu Y, Ekstrom T, Bateman ED. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005, 171:129-136.
10. Reddel HK. Goals of asthma treatment: how high should we go?. Eur Respir J 2004, 24:715-717. 10.1183/09031936.04.10104904, 15516658.
11. Briggs AH, Bousquet J, Wallace MV, Busse WW, Clark TJ, Pedersen SE, Bateman ED. Cost-effectiveness of asthma control: an economic appraisal of the GOAL study. Allergy 2006, 61:531-536. 10.1111/j.1398-9995.2006.01038.x, 16629780.
12. Akazawa M, Stempel DA. Single-inhaler combination therapy for asthma: a review of cost effectiveness. Pharmacoeconomics 2006, 24:971-988. 10.2165/00019053-200624100-00005, 17002480.
13. Pavord ID, Shaw D. The use of exhaled nitric oxide in the management of asthma. J Asthma 2008, 45:523-531. 10.1080/02770900801978557, 18773320.
14. Szefler SJ, Mitchell H, Sorkness CA, Gergen PJ, O'Connor GT, Morgan WJ, Kattan M, Pongracic JA, Teach SJ, Bloomberg GR, Eggleston PA, Gruchalla RS, Kercsmar CM, Liu AH, Wildfire JJ, Curry MD, Busse WW. Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trial. Lancet 2008, 372:1065-1072. 10.1016/S0140-6736(08)61448-8, 2610850, 18805335.
15. Smith AD, Cowan JO, Brassett KP, Herbison GP, Taylor DR. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 2005, 352:2163-2173. 10.1056/NEJMoa043596, 15914548.
16. Shaw DE, Berry MA, Thomas M, Green RH, Brightling CE, Wardlaw AJ, Pavord ID. The use of exhaled nitric oxide to guide asthma management: a randomized controlled trial. Am J Respir Crit Care Med 2007, 176:231-237. 10.1164/rccm.200610-1427OC, 17496226.
17. Van der Meer V, Rikkers-Mutsaerts ER, Sterk PJ, Thiadens HA, Assendelft WJ, Sont JK. Compliance and reliability of electronic PEF monitoring in adolescents with asthma. Thorax 2006, 61:457-458. 10.1136/thx.2005.054619, 2111179, 16648355.
18. Van den Nieuwenhof L, Schermer T, Eysink P, Halet E, van Weel C, Bindels P, Bottema B. Can the Asthma Control Questionnaire be used to differentiate between patients with controlled and uncontrolled asthma symptoms? A pilot study. Fam Pract 2006, 23:674-681. 10.1093/fampra/cml041, 16880177.
19. Puffer S, Torgerson DJ, Watson J. Cluster randomized controlled trials. J Eval Clin Pract 2005, 11:479-483. 10.1111/j.1365-2753.2005.00568.x, 16164589.
20. Humbert M, Holgate S, Boulet LP, Bousquet J. Asthma control or severity: that is the question. Allergy 2007, 62:95-101.
21. Taylor DR, Pijnenburg MW, Smith AD, De Jongste JC. Exhaled nitric oxide measurements: clinical application and interpretation. Thorax 2006, 61:817-827. 10.1136/thx.2005.056093, 2117092, 16936238.
22. Schellevis FC, de Bakker DH, Verheij RA, Hingstman L. Hoe is de huisartsenzorg georganiseerd?. Volksgezondheid Toekomst Verkenning, Nationaal Kompas Volksgezondheid 1999, Bilthoven: RIVM.
23. Juniper EF, Bousquet J, Abetz L, Bateman ED. Identifying 'well-controlled' and 'not well-controlled' asthma using the Asthma Control Questionnaire. Respir Med 2006, 100:616-621. 10.1016/j.rmed.2005.08.012, 16226443.
24. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J. Standardisation of spirometry. Eur Respir J 2005, 26:319-338. 10.1183/09031936.05.00034805, 16055882.
25. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med 2005, 171:912-930.
26. Alving K, Janson C, Nordvall L. Performance of a new hand-held device for exhaled nitric oxide measurement in adults and children. Respir Res 2006, 7:67. 10.1186/1465-9921-7-67, 1462993, 16626491.
27. Dressel H, de la MD, Reichert J, Ochmann U, Petru R, Angerer P, Holz O, Nowak D, Jorres RA. Exhaled nitric oxide: independent effects of atopy, smoking, respiratory tract infection, gender and height. Respir Med 2008, 102:962-969. 10.1016/j.rmed.2008.02.012, 18396030.
28. Reddel H, Ware S, Marks G, Salome C, Jenkins C, Woolcock A. Differences between asthma exacerbations and poor asthma control. Lancet 1999, 353:364-369. 10.1016/S0140-6736(98)06128-5, 9950442.
29. Rabe KF, Atienza T, Magyar P, Larsson P, Jorup C, Lalloo UG. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet 2006, 368:744-753. 10.1016/S0140-6736(06)69284-2, 16935685.
30. Van den Hout WB, Tijhuis GJ, Hazes JM, Breedveld FC, Vliet Vlieland TP. Cost effectiveness and cost utility analysis of multidisciplinary care in patients with rheumatoid arthritis: a randomised comparison of clinical nurse specialist care, inpatient team care, and day patient team care. Ann Rheum Dis 2003, 62:308-315. 10.1136/ard.62.4.308, 1754484, 12634227.
31. Foundation for Accountability FACCT quality measurement guide. Adult asthma version 2.0 1999, Foundation for Accountability., http://www.facct.org/doclibFiles/documentFile_118.pdf.
32. Broadbent E, Petrie KJ, Main J, Weinman J. The brief illness perception questionnaire. J Psychosom Res 2006, 60:631-637. 10.1016/j.jpsychores.2005.10.020, 16731240.
33. Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: The development and evaluation of a new method for assessing the cognitive representation of medicine. Psychol Health 1999, 14:1-24.
34. Fialko L, Garety PA, Kuipers E, Dunn G, Bebbington PE, Fowler D, Freeman D. A large-scale validation study of the Medication Adherence Rating Scale (MARS). Schizophr Res 2008, 100:53-59. 10.1016/j.schres.2007.10.029, 18083007.
35. Menckeberg TT, Bouvy ML, Bracke M, Kaptein AA, Leufkens HG, Raaijmakers JA, Horne R. Beliefs about medicines predict refill adherence to inhaled corticosteroids. J Psychosom Res 2008, 64:47-54. 10.1016/j.jpsychores.2007.07.016, 18157999.
36. Juniper EF, Guyatt GH, Ferrie PJ, Griffith LE. Measuring quality of life in asthma. Am Rev Respir Dis 1993, 147:832-838.
37. Brazier J, Usherwood T, Harper R, Thomas K. Deriving a preference-based single index from the UK SF-36 Health Survey. J Clin Epidemiol 1998, 51:1115-1128. 10.1016/S0895-4356(98)00103-6, 9817129.
38. Revicki DA, Leidy NK, Brennan-Diemer F, Sorensen S, Togias A. Integrating patient preferences into health outcomes assessment: the multiattribute Asthma Symptom Utility Index. Chest 1998, 114:998-1007. 10.1378/chest.114.4.998, 9792568.
39. Stiggelbout AM, de Haes JC. Patient preference for cancer therapy: an overview of measurement approaches. J Clin Oncol 2001, 19:220-230.
40. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997, 35:1095-1108. 10.1097/00005650-199711000-00002, 9366889.
41. Szende A, Svensson K, Stahl E, Meszaros A, Berta GY. Psychometric and utility-based measures of health status of asthmatic patients with different disease control level. Pharmacoeconomics 2004, 22:537-547. 10.2165/00019053-200422080-00005, 15217309.
42. Walters SJ, Brazier JE. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res 2005, 14:1523-1532. 10.1007/s11136-004-7713-0, 16110932.
43. Willan AR. Analysis, sample size, and power for estimating incremental net health benefit from clinical trial data. Control Clin Trials 2001, 22:228-237. 10.1016/S0197-2456(01)00110-6, 11384787.
44. Schermer TR, Thoonen BP, van den BG, Akkermans RP, Grol RP, Folgering HT, van Weel C, van Schayck CP. Randomized controlled economic evaluation of asthma self-management in primary health care. Am J Respir Crit Care Med 2002, 166:1062-1072. 10.1164/rccm.2105116, 12379549.
45. Campbell MK, Thomson S, Ramsay CR, MacLennan GS, Grimshaw JM. Sample size calculator for cluster randomized trials. Comput Biol Med 2004, 34:113-125. 10.1016/S0010-4825(03)00039-8, 14972631.
46. Van Den Brink M, Van Den Hout WB, Stiggelbout AM, Van De Velde CJ, Kievit J. Cost measurement in economic evaluations of health care: Whom to ask?. Med Care 2004, 42:740-746. 10.1097/01.mlr.0000132351.78009.a1, 15258475.
47. Oostenbrink JB, Koopmanschap MA, Rutten FF. Standardisation of costs: the Dutch Manual for Costing in economic evaluations. Pharmacoeconomics 2002, 20:443-454. 10.2165/00019053-200220070-00002, 12093300.
48. Lamers LM, McDonnell J, Stalmeier PF, Krabbe PF, Busschbach JJ. The Dutch tariff: results and arguments for an effective design for national EQ-5D valuation studies. Health Econ 2006, 15:1121-1132. 10.1002/hec.1124, 16786549.
49. van den Nieuwenhof L, Schermer T, Heins M, Grootens J, Eysink P, Bottema B, van Weel C, Bindels P. Tracing uncontrolled asthma in family practice using a mailed asthma control questionnaire. AnnFam Med 2008, 6(Suppl 1):s16-s22.
50. Petsky HL, Cates CJ, Lasserson TJ, Li AM, Turner C, Kynaston JA, Chang AB. A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils). Thorax
51. Reddel HK, Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, Casale TB, Chanez P, Enright PL, Gibson PG, de Jongste JC, Kerstjens HA, Lazarus SC, Levy ML, O'Byrne PM, Partridge MR, Pavord ID, Sears MR, Sterk PJ, Stoloff SW, Sullivan SD, Szefler SJ, Thomas MD, Wenzel SE, . American Thoracic Society/European Respiratory Society Task Force on Asthma Control and Exacerbations An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009, 180:59-99. 10.1164/rccm.200801-060ST, 19535666, American Thoracic Society/European Respiratory Society Task Force on Asthma Control and Exacerbations.